Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial
<h4>Background</h4> <p>Tumour necrosis factor inhibition (TNFi) and B cell depletion are highly effective treatments for active rheumatoid arthritis (RA) but to date no randomised controlled trials have directly compared their safety, efficacy and cost effectiveness. This study wa...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2016
|